By using this site, you agree to our Privacy Policy 

Leadership

2010 News Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
DateTitle  
12/27/10Emergent BioSolutions Starts Phase I Clinical Trial for Third Generation Anthrax Vaccine Printer Friendly Version
12/08/10Emergent BioSolutions to Webcast Presentation at JPMorgan Healthcare Conference Printer Friendly Version
12/06/10Emergent BioSolutions Presents Positive Data from Its TRU-016 Program at American Society of Hematology Meeting Printer Friendly Version
11/09/10Emergent BioSolutions Awarded Five Therapeutic Discovery Project Grants Printer Friendly Version
11/09/10Emergent BioSolutions Announces Acceptance of TRU-016 and TRU-Adhance Abstracts for Presentation at American Society of Hematology Meeting Printer Friendly Version
11/08/10Emergent BioSolutions to Webcast Presentations at Upcoming Investor Conferences Printer Friendly Version
11/04/10Emergent BioSolutions Reports Financial Results for Third Quarter and First Nine Months of 2010 Printer Friendly Version
11/04/10Emergent BioSolutions Receives Orphan Drug Designation for Its Investigational Monoclonal Antibody for the Treatment of Inhalation Anthrax Printer Friendly Version
11/03/10Emergent BioSolutions Receives Loan Repayment from Protein Sciences Corporation Printer Friendly Version
10/28/10Emergent BioSolutions Completes Acquisition of Trubion Pharmaceuticals Printer Friendly Version
10/13/10Emergent BioSolutions to Release Third Quarter 2010 Financial Results and Conduct a Conference Call on November 4, 2010 Printer Friendly Version
10/08/10Emergent BioSolutions Launches Singapore Operations Printer Friendly Version
10/01/10Emergent BioSolutions Receives Fast Track Designation for Its Investigational Monoclonal Antibody for the Treatment of Inhalational Anthrax Printer Friendly Version
09/27/10Emergent BioSolutions to Participate in October 2010 Investor Conferences Printer Friendly Version
09/17/10Emergent BioSolutions Awarded HHS Contract Valued at up to $186.6 Million to Develop rPA Anthrax Vaccine Printer Friendly Version
09/08/10Emergent BioSolutions Announces Early Termination of HSR Waiting Period for Its Acquisition of Trubion Pharmaceuticals Printer Friendly Version
09/08/10Emergent BioSolutions Announces Commencement of Phase I Clinical Trial for Monoclonal Antibody to Treat Inhalational Anthrax  Printer Friendly Version
09/01/10Emergent BioSolutions Awarded NIAID Contract That Increases Potential Funding to Over $58 Million for Advanced Development of Third Generation Anthrax Vaccine Printer Friendly Version
08/24/10Emergent BioSolutions Hosts Symposium for Biomedical Research Scholars Printer Friendly Version
08/24/10Emergent BioSolutions Announces Appointment of John E. Niederhuber, M.D. to the Company's Board of Directors Printer Friendly Version
08/12/10Emergent BioSolutions to Acquire Trubion Pharmaceuticals Printer Friendly Version
08/11/10Emergent BioSolutions and Temasek Life Sciences Ventures Establish Joint Venture to Develop Broad Spectrum Pandemic Flu Vaccine and Therapeutic Printer Friendly Version
08/05/10Emergent BioSolutions Reports Financial Results for Second Quarter and First Six Months of 2010 Printer Friendly Version
07/20/10Emergent Revises Upward 2010 Financial Forecast Printer Friendly Version
07/16/10Maryland Governor Martin O'Malley Leads Ribbon Cutting Ceremony at Emergent's Baltimore Manufacturing Facility Printer Friendly Version
07/14/10Emergent BioSolutions Awarded HHS Contract Valued at Up to $107 Million to Develop Large-Scale Manufacturing for BioThrax Printer Friendly Version
07/13/10Emergent BioSolutions to Release Second Quarter 2010 Financial Results and Conduct a Conference Call on August 5, 2010 Printer Friendly Version
07/12/10Emergent BioSolutions Hosts Biopreparedness Roundtable for NATO Parliamentarians Printer Friendly Version
06/24/10Emergent BioSolutions Completes Deliveries of BioThrax to Allied Foreign Governments Printer Friendly Version
06/04/10Emergent BioSolutions Announces Appointment of Marvin White to the Company's Board of Directors Printer Friendly Version
06/01/10Emergent BioSolutions to Participate in June 2010 Investor Conferences Printer Friendly Version
05/19/10Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 20, 2010 at 10:00 am Eastern; Webcast Will Be Available Printer Friendly Version
05/17/10Emergent BioSolutions IND for Anthrax Monoclonal Antibody Therapeutic Clears FDA Review Printer Friendly Version
05/13/10Emergent BioSolutions Recognized as Biotechnology Firm of the Year by Tech Council of Maryland Printer Friendly Version
05/06/10Emergent BioSolutions Hosts Biopreparedness Forum for Members of the NATO Parliamentary Assembly Printer Friendly Version
05/05/10Emergent BioSolutions Reports Financial Results for First Quarter 2010 Printer Friendly Version
05/03/10Emergent BioSolutions to Participate on Vaccine Panel at BIO International Convention 2010 Printer Friendly Version
04/21/10Emergent BioSolutions to Release First Quarter 2010 Financial Results and Conduct a Conference Call on May 5, 2010 Printer Friendly Version
03/11/10Emergent BioSolutions Chairman and CEO Fuad El-Hibri Recognized as Outstanding International Business Leader Printer Friendly Version
03/04/10Emergent BioSolutions Reports Financial Results for Full Year 2009 Printer Friendly Version
02/22/10Emergent BioSolutions to Participate in March 2010 Investor Conferences Printer Friendly Version
01/25/10Emergent BioSolutions to Release Fourth Quarter and Full Year 2009 Financial Results and Conduct a Conference Call on March 4, 2010 Printer Friendly Version
01/11/10Emergent BioSolutions Announces R. Don Elsey, Chief Financial Officer, to Join Board of Directors of MdBio Foundation Printer Friendly Version
01/11/10Emergent BioSolutions Provides Preliminary 2009 Financial Results and Guidance for 2010 Printer Friendly Version

Investor Toolkit